Abstract: A series of novel benzohydrazide derivatives containing dihydropyrazoles have been synthesized as potential epidermal growth factor receptor (EGFR) kinase inhibitors and their biological activities as potential antiproliferative agents have been evaluated. Among these compounds, compound H20 exhibited the most potent antiproliferative activity against four cancer cell line variants (A549, MCF-7, HeLa, HepG2) with IC 50 values of 0.46, 0.29, 0.15 and 0.21 µM respectively, which showed the most potent EGFR inhibition activities (IC 50 = 0.08 µM for EGFR). Molecular modeling simulation studies were performed in order to predict the biological activity and activity relationship (SAR) of these benzohydrazide derivatives. These results suggested that compound H20 may be a promising anticancer agent.
Introduction
Cancer has become one of the most serious diseases which represents a great threat to human health around the world [1] . Although there are currently a large number of anticancer drugs, more and more people continue to die of cancer [2] . Epidermal growth factor receptor (EGFR) plays important roles in human cancer. As a member of the HER family, EGFR is a tyrosine kinase receptor which plays an essential role in normal cell growth and differentiation, and is involved in tumor proliferation and survival [3, 4] . The HER family comprises four members: EGFR (HER1/ErbB-1), ErbB-2 (HER2/neu), , and ErbB-4 (HER4) [5] . EGFR is one of the most important targets in current cancer research and its over-expression or abnormal activation often causes cell malignant transformation [6] . The over-expression of EGFR has been observed in many solid tumors, such as colon [7] , ovarian [8] , breast and non-small cell lung cancer (NSCLC) [9] . Therefore, EGFR inhibition has been developed as one of the most efficient strategies for cancer therapy.
Dihydropyrazole, a small bioactive molecule, is a prominent structural motif found in numerous pharmaceutically active compounds. Some representatives had been demonstrated to have important biological activities such as antiviral/antitumor [10] , antibacterial [11] , fungistatic [12] , antihyperglycemic activity [13] , antimalarial [14] and antitubercular effects [15] . Biological evaluation some of the synthesized compounds were potent inhibitors of EGFR. Some novel compounds containing the dihydropyrazole skeletons were reported as potent anticancer agents against EGFR tyrosine kinase. It had been reported that anticancer compounds such as 3-alkoxy-1H-pyrazolo [3,4-d] pyrimidines analogues (3A-1-PP, Figure 1 ) showed potent EGFR kinase inhibitory activity, with IC50 values reaching single digit nanomolar values [16] . Compounds a, b, c and d (Figure 1 ) displayed the most potent EGFR inhibitory activity, with IC50 values of 0.07, 0.24, 0.06 and 0.26 μM respectively, which were comparable to the positive control erlotinib (IC50 = 0.03 μM) [17] [18] [19] [20] . Compound e containing the dihydropyrazole and naphthalene ring showed the highest inhibitory EGFR activity (IC50 = 0.12 μM) [21] . Some naphthalene derivatives have been reported as potent microtubule inhibitors, apoptosis inducers, glutamamide analogues or P-glycoprotein inhibitors [22, 23] . On the other hand, the naphthalene ring can be recognized in various biologically active compounds with clinical applications. Naftifine and terbinafine, allylamine antifungal agents, are widely used for the treatment of fungal infections [24] [25] [26] . Propranolol is an anti-angina drug, duloxetine is used for the treatment of depression, nafimidone and its oxime ester derivative can be further developed for the treatment of epilepsy [27] . Therefore, preparation and extensive biological evaluations on naphthalene derivatives have continuously attracted our attention [28] . Besides, benzohydrazides are reported to possess a wide variety of biological activities like antiglycation [29] , antioxidant [30] , antileishmanial [22] , antibacterial [31] , antifungal [23] , antitumor [32] and anticonvulsant [24] . Benzothiazole Schiff bases with diverse biological activities have also been reported [26] .
The three combined substructures-the dihydropyrazole along with the naphthalene ring and benzohydrazides-might exhibit synergistic anticancer effects. All of these facts encouraged us to integrate these three moieties and screen new benzohydrazide derivatives containing dihydropyrazoles Some naphthalene derivatives have been reported as potent microtubule inhibitors, apoptosis inducers, glutamamide analogues or P-glycoprotein inhibitors [22, 23] . On the other hand, the naphthalene ring can be recognized in various biologically active compounds with clinical applications. Naftifine and terbinafine, allylamine antifungal agents, are widely used for the treatment of fungal infections [24] [25] [26] . Propranolol is an anti-angina drug, duloxetine is used for the treatment of depression, nafimidone and its oxime ester derivative can be further developed for the treatment of epilepsy [27] . Therefore, preparation and extensive biological evaluations on naphthalene derivatives have continuously attracted our attention [28] . Besides, benzohydrazides are reported to possess a wide variety of biological activities like antiglycation [29] , antioxidant [30] , antileishmanial [22] , antibacterial [31] , antifungal [23] , antitumor [32] and anticonvulsant [24] . Benzothiazole Schiff bases with diverse biological activities have also been reported [26] . The three combined substructures-the dihydropyrazole along with the naphthalene ring and benzohydrazides-might exhibit synergistic anticancer effects. All of these facts encouraged us to integrate these three moieties and screen new benzohydrazide derivatives containing dihydropyrazoles as potential EGFR inhibitory agents. Herein we disclose the design and synthesis of some novel benzohydrazide derivatives containing dihydropyrazoles as potential EGFR kinase inhibitors, and their antitumor activity against the A549 (human lung cancer), MCF-7 (human breast cancer), HeLa (human cervical cancer) and HepG2 (human hepatocellular cancer) cancer cell lines.
Results and Discussion

Chemistry
A series of novel benzohydrazide derivatives containing dihydropyrazole moieties were synthesized by the routes outlined in Scheme 1. The structures of the compounds are listed in Table 1 . Methyl 4-hydrazinylbenzoate (B) was synthesized from 4-hydrazinylbenzoic acid in methanol at room temperature. The diverse substituted chalcones E1-E16 were obtained by stirring substituted acetophenones and naphthaldehyde in ethanol at room temperature for 6-8 h. The cyclization different chalcones and methyl 4-hydrazinylbenzoate in refluxing ethanol gives compounds F1-F16. [20] [21] [22] [23] [24] (ii) EtOH, KOH, room temperature, [6] [7] [8] (iii) EtOH, HAc, 80 °C, [20] [21] [22] [23] [24] (iv) MeOH, N2H4·H2O (80%), DMF, 70 °C, [20] [21] [22] [23] [24] (v) RCHO, EtOH, HOAc, room temperature, [6] [7] [8] Compounds F1-F16 further reacted with excess hydrazine hydrate (80%) to give the requisite intermediate G1-G16. The desired compounds H1-H32 were generated by the reaction of compounds G1-G16 with substituted benzaldehydes in ethanol for 6-8 h. Purified compounds H1-H32 were finally obtained by chromatography. All synthesized compounds H1-H32 gave satisfactory analytical and spectroscopic data in full accordance with their depicted structures, and other data published in a Chinese patent [33] .
Bioassays
Antiproliferative Assay
The antiproliferative activities of the newly synthesized derivatives H1-H32 were evaluated under identical conditions by the MTT assay against four cultured cell lines (A549, MCF-7, HeLa and HepG2) with erlotinib as control. The IC50 values of the compounds against these human cancer cells are summarized in Table 2 . As shown, the results revealed that all of the target compounds exhibited significant antiproliferative activities, ranging from 0.15 to 100 μM. Compounds F1-F16 further reacted with excess hydrazine hydrate (80%) to give the requisite intermediate G1-G16. The desired compounds H1-H32 were generated by the reaction of compounds G1-G16 with substituted benzaldehydes in ethanol for 6-8 h. Purified compounds H1-H32 were finally obtained by chromatography. All synthesized compounds H1-H32 gave satisfactory analytical and spectroscopic data in full accordance with their depicted structures, and other data published in a Chinese patent [33] .
Bioassays
Antiproliferative Assay
The antiproliferative activities of the newly synthesized derivatives H1-H32 were evaluated under identical conditions by the MTT assay against four cultured cell lines (A549, MCF-7, HeLa and HepG2) with erlotinib as control. The IC 50 values of the compounds against these human cancer cells are summarized in Table 2 . As shown, the results revealed that all of the target compounds exhibited significant antiproliferative activities, ranging from 0.15 to 100 µM. 20, 0.12, 0.17 and 0.10 µM) . These results suggested that compound H20 is more potent than the other compounds overall. Modification of substituents such as methyl, halogen, methoxyl, ethyl and ethoxy was performed to explore the structure-activity relationships of these compounds. Compounds bearing one methyl group at the para-position in the A ring showed stronger antiproliferative activity (the IC 50 values of H4 and H20: 0.45 and 0.21 µM against HeLa cells) than those with hydrogen (H1 and H17), fluorine (H11 and H27), chlorine (H14 and H30), bromine (H16 and H32), ethyl (H5 and H21), ethoxy (H8 and H24) and methoxyl (H6 and H22) substituents, in the order of Me > H > Br > Cl > F, Me > OMe and Et > OEt. This means that compounds with electron-donating groups at the para-position of the A ring had better antiproliferative activity than those with electron-withdrawing groups. A comparison of the composition on the A ring was as follows: for compounds H2-H4, H9-H11, H13-H14, H18-H20, H25-H27 and H29-H30, the potency order of substituent groups on the A ring was found to be para > ortho > meta. Compounds H9-H15 and H25-H31 with halogen groups on the A ring exhibited antiproliferative activities in the order of disubstituted > monosubstituted. Interestingly, compounds H6 and H22 with one methoxyl group on the A ring showed stronger antiproliferative activities than compounds H7 and H23 with three methoxyl groups, so we concluded that more electron-donating groups could reduce the electron density of the A ring and make it difficult to form π-π bonds with amino acids containing aromatic groups.
In the case of constant A ring substituents, changes of substituents on the B ring can also affect the activities of these compounds. Contrary to the A ring, derivatives H17-H32 with a methoxyl at the para-position displayed better activities than at the meta-position (compounds H1-H16). These indicated that the position of the substituent had an influence on the antitumoral activity.
Kinase Inhibitory Activity
All these newly synthesized compounds were evaluated for their inhibitory activities against EGFR kinases using a solid-phase ELISA assay. The approved EGFR inhibitor drug erlotinib was used as a positive control. The inhibition constants (IC 50 ) of the compounds were summarized in Table 3 . The EGFR kinase inhibitory activity results of the tested compounds correlated with the structural relationships (SAR) of their inhibitory effects on the cell proliferation assay. Among the tested compounds, compound H20 showed potent anticancer activity with IC 50 of 0.08 µM, which was comparable to the positive control erlotinib (IC 50 = 0.03 µM). Other tested compounds displayed moderate inhibitory activities, with IC 50 values ranging from 0.35 µM to 24.58 µM. This suggests that the potent inhibitory effects of the synthetic compounds on the cell proliferation assay were basically related to their kinase inhibitory activities.
Cytotoxicity Test
All the target compounds H1-H32 were evaluated for their toxicity against 293T human kidney epithelial cells at the median cytotoxic concentration (CC 50 ) value of the tested compounds determined by the MTT assay. As displayed in Table 4 , these compounds were tested at multiple doses to study the viability of 293T cells. Judging from the median cytotoxic concentration (CC 50 ) data, all of the tested compounds demonstrated similar cytotoxic activities as erlotinib in vitro against human kidney epithelial 293T cell. 
Analysis of Apoptosis
To verify whether the inhibition of cell growth of HeLa cell lines was related to cell apoptosis, we decided to use flow cytometry with an Annexin V-FITC/PI Apoptosis Detection Kit to induce the HeLa cell apoptosis with compound H20. The uptake of Annexin V-FITC/PI markedly increased, and the uptake of normal cells was significantly decreased in a time-dependent manner. According to the annotated data, the percentage of apoptotic cells was significantly elevated directly and in a dose-dependent manner. The results are shown in Figures 2 and 3. As can be seen, the percentages of cell apoptosis were 9.01%, 28.7%, 34.9%, 47.7%, 58.12%, in response to 0, 2.0, 4.0, 6.0, 8.0 µM concentrations of compound H20, respectively. This leads to the conclusion that the percentage of apoptotic cells significantly increased after treatment with high doses of H20.
Molecular Docking
To gain better understanding of the potency of the 32 compounds and guide further SAR studies, we examined the interaction of these compounds with EGFR (PDB code: 1M17) by molecular docking. A simulation of binding between the compounds and the ATP binding sites in EGFR was performed. All docking runs used the DS 4.5 software (Discovery Studio 4.5, Accelrys, Co. Ltd., Beijing, China). The obtained results, presented in Figures 4 and 5, show the optimal binding mode of compound H20 interacting with the 1M17 protein. The amino acid residues of EGFR which had interactions with compound H20 were labeled. In the proposed binding mode, compound H20 was nicely bound to the ATP binding pocket of EGFR through hydrogen bond interactions and hydrophobic interactions.
In the binding model, compound H20 was well bound to the EGFR protein with Gln767, Thr766, Arg752, Val702, Leu694, Leu820, Ala719, the seven amino acids located in the binding pocket of the protein, playing an important role in the combination with compound H20. As we can see from Figures 4 and 5, Gln767 formed conventional hydrogen bonds and Thr766 formed Van der Waals bonds with the nitrogen atom of the Schiff base group, which enhanced the combination activity of compound H20. Moreover, a carbon-hydrogen bond and π-sulfur bonds were found between Arg828 and Cys751 with a benzene ring. Meanwhile the Leu694 formed three alkyl bonds with the methyl, benzene ring and dihydropyrazole ring. Alkyl and π-alkyl bonds were displayed in presence of Leu820 and dihydropyrazole ring and benzene ring, respectively. Moreover, Ala719 also formed π-alkyl bonds with the benzene ring. Naphthalene was also bonded with Val702 by a π-alkyl bond. In molecular docking 3D modeling, compound H20 was nicely bound to the ATP binding site through the hydrogen bond with the backbone of Gln767 (distance = 2.4 Å) which increased the binding affinity dramatically in theory, as displayed in Figure 5 .
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Experimental Section
General Information
All chemicals and reagents used in current study were commercially available analytical or chemically pure grade reagents, unless otherwise indicated. All the reactions were monitored by thinlayer chromatography (TLC) on glass-backed silica gel sheets (silica GF 254) and visualized using UV (254 or 365 nm). Column chromatography separations were performed on silica gel (200-300 mesh) using EtOAc/petroleum ether as eluents. Melting points (uncorrected) were determined using an X-4 MP apparatus (Taike Corp, Beijing, China). All the 1 H-NMR and 13 C-NMR spectra were recorded using a model DPX400 spectrometer (Bruker, Billerica, MA, USA) in DMSO-d6 and chemical shifts were reported in δ (ppm) units relative to the internal standard tetramethylsilane (TMS). Mass spectra (MS) were recorded using a Mariner System 5304 mass spectrometer (Isoprime, Manchester, UK).
General Synthesis Procedure of Benzohydrazide Derivatives Containing Dihydropyrazole Moieties
Synthesis of Methyl 4-Hydrazinylbenzoate (B)
4-Hydrazinylbenzoic acid (3.0 g, 0.020 mol) was suspended in anhydrous methanol (30 mL) and thionyl chloride (5 mL) was added dropwise at 0 °C over 30 min. Then the reaction mixture was stirred at room temperature for 20-24 h, the precipitate that formed was filtered, washed with petroleum ether and ethanol (5:1) three times to remove residual 4-hydrazinylbenzoic acid, and dried to give the title 4-hydrazinylbenzoate.
General Synthetic Procedure for Diverse Substituted Chalcones E1-E16
The diverse substituted chalcones E1-E16 were synthesized by reacting the appropriate substituted acetophenone (3.0 mmol) and one equivalent of naphthaldehyde (0.5 g, 3.0 mmol) using 40% potassium hydroxide (2 mL) as catalyst in ethanol (20 mL). The reaction mixture was stirred at room temperature 
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General Synthesis Procedure of Benzohydrazide Derivatives Containing Dihydropyrazole Moieties
Synthesis of Methyl 4-Hydrazinylbenzoate (B)
4-Hydrazinylbenzoic acid (3.0 g, 0.020 mol) was suspended in anhydrous methanol (30 mL) and thionyl chloride (5 mL) was added dropwise at 0˝C over 30 min. Then the reaction mixture was stirred at room temperature for 20-24 h, the precipitate that formed was filtered, washed with petroleum ether and ethanol (5:1) three times to remove residual 4-hydrazinylbenzoic acid, and dried to give the title 4-hydrazinylbenzoate.
General Synthetic Procedure for Diverse Substituted Chalcones E1-E16
The diverse substituted chalcones E1-E16 were synthesized by reacting the appropriate substituted acetophenone (3.0 mmol) and one equivalent of naphthaldehyde (0.5 g, 3.0 mmol) using 40% potassium hydroxide (2 mL) as catalyst in ethanol (20 mL). The reaction mixture was stirred at room temperature for 6-8 h, the yellow precipitate that formed was filtered, washed with petroleum ether and ethanol (5:1) three times to remove impurities, and dried to give the diverse substituted chalcones.
General Synthetic Procedure for Diverse Substituted Chalcones F1-F16
Added acetic acid (1 mL) was used as an catalytic agent. The cyclization reaction of different substituted chalcones E1-E16 (3.0 mmol) and methyl 4-hydrazinylbenzoate (3.0 mmol) was performed in refluxing ethanol (20 mL) at 80˝C for 20-24 h to afford compounds F1-F16, as monitored by thin layer chromatography (TLC). The crude products were purified in good yields by recrystallization from ethanol, ethyl acetate and acetone (1:1:0.05).
General Synthetic Procedure for Compounds G1-G16
Compounds F1-F16 (3.0 mmol) were dissolved in DMF (10 mL) and excess hydrazine hydrate (80%, 5 mL) was added dropwise in methanol (20 mL). The solution was refluxed at 70˝C for 20-24 h, and then poured into water (50 mL) and extracted with ethyl acetate (3ˆ30 mL). The organic layer was collected, and washed with brine. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo to obtain yields 60%-80% of crude products G1-G16.
General Synthetic Procedure for the Title Compounds H1-H32
Equimolar amounts of compounds G1-G16 (2.0 mmol) and 3-or 4-methoxybenzaldehyde (2.0 mmol) were dissolved in ethanol (20 mL), then acetic acid (1 mL) was added as catalytic agent. The reaction mixture solution continued to stirred at room temperature for 6-8 h. The resulting solid was extracted with petroleum ether for column chromatography. Column chromatography was performed using silica gel (200-300 mesh), eluting with ethyl acetate and petroleum ether (1:2, v/v), to give the title products. All of the target compounds gave satisfactory analytical and 1 H-NMR (in Supplementary Materials) and MS spectroscopic data, in accordance with their depicted structures. 161.08, 149.84, 139.88, 133.40, 132.34, 129.71, 129.66, 129.40, 129.21, 128.13, 128.08, 127.57, 126.97, 126.50, 125.07, 124.26, 123.28, 114.75, 112.49, 63.20, 60.40, 55.72, 43.22 12, 161.08, 148.84, 139.90, 133.46, 132.34, 129.71, 129.66, 129.50, 129.21, 128.13, 127.57, 126.97, 126.50, 125.07, 124.26, 123.28, 114.75, 112.49, 60.33, 55.73, 43.42 161.07, 149.84, 139.88, 133.40, 132.34, 129.71, 129.66, 129.40, 129.21, 128.13, 128.08, 127.57, 126.97, 126.50, 125.07, 124.26, 123.28, 114.75, 112.49, 60.23, 55.72, 43.35 , 5.61; N, 10.40. Found: C, 77.94; H, 5.54; N, 10.35 . 14, 138.88, 133.40, 129.71, 129.66, 129.40, 129.21, 128.13, 128.08, 127.57, 126.97, 126.50, 125.07, 124.26, 123.28, 114.75, 112.49, 60.54, 55.72, 43.35 , 5.61; N, 10.40. Found: C, 77.95; H, 5.56; N, 10.36 . 161.06, 160.56, 149.95, 149.85, 146.85, 146.77, 145.72, 140.01, 139.94, 133.40, 132.88, 129.62, 129.39, 128.92, 128.61, 128.23, 128.07, 127.59, 126.95, 126.63, 126.57, 125.02, 124.91, 124.27, 122.85, 114.75, 114.67, 112.26, 60.22, 55.72, 43.57, 43.44 , 5.84; N, 10.14. Found: C, 78.12; H, 5.79; N, 10.11 . 149.96, 146.81, 146.72, 145.73, 139.95, 133.40, 132.88, 129.86, 129.64, 129.38, 128.92, 128.62, 128.24, 128.07, 127.58, 126.96, 126.64, 125.04, 124.26, 123.09, 114.75, 112.38, 63.08, 55.72, 43.57, 43.42 , 5.45; N, 10.10. Found: C, 75.67; H, 5.43; N, 10.02 . 4H); 7.23 (s, 2H); 2H); 2H); J = 8.68 Hz, 2H); 4H); 8.33 (s, 1H); 11.53 (s, 1H) . 13 C-NMR (DMSO-d 6 ): 163.92, 163.63, 162.97, 162.32, 162.23, 161.09, 160.70, 147.83, 146.98, 146.16, 139.53, 136.01, 135.94, 135.87, 133.37, 132.92, 129.70, 129.64, 129.37, 128.95, 128.08, 127.53, 127.13, 126.67, 125.14, 124.24, 123.98, 114.75, 112.91, 109.54, 109.36, 104.85, 104.68, 104.51, 63.60, 55.72, 42.98 , 5.58; N, 9.11. Found: C, 72.18; H, 5.56; N, 9.08 . 161.07, 159.98, 149.86, 146.85, 146.76, 140.01, 133.40, 132.87, 129.62, 129.38, 128.91, 128.43, 128.17, 128.07, 127.59, 126.95, 126.56, 125.02, 124.75, 124.27, 122.82, 115.08, 112.24, 63.69, 63.24, 55.72, 43.45 , 5.67; N, 9.85. Found: C, 75.90; H, 5.65; N, 9.81 . 163.97, 163.08, 161.91, 161.07, 149.52, 146.87, 146.76, 139.32, 133.39, 132.90, 129.67, 129.40, 128.98, 128.97, 128.94, 128.75, 128.24, 128.07, 127.57, 126.61, 125.08, 124.24, 123.30, 116.16, 114.75, 112.49, 63.42, 60.43, 55.72, 43.42 , 5.02; F, 3.50; N, 10.33. Found: C, 75.16; H, 5.01; F, 3.48; N, 10.30 . 163.87, 163.08, 162.31, 161.07, 149.32, 146.87, 146.66, 139.82, 133.39, 132.90, 129.66, 129.40, 128.99, 128.97, 128.94, 128.77, 128.71, 128.24, 128.07, 127.57, 126.61, 125.08, 124.24, 123.30, 116.16, 114.74, 112.49, 63.42, 60.23, 55.72, 43.42 , 5.02; N, 10.33. Found: C, 75.14; H, 5.00; N, 10.31 . 163.87, 162.35, 161.07, 150.32, 146.87, 146.66, 139.82, 134.39, 132.90, 129.66, 129.40, 128.99, 128.97 128.94, 128.77, 128.71, 128.24, 128.07, 127.57, 126.61, 125.08, 124.24, 123.30, 116.16, 114.74, 112.49, 63.45, 60.33, 55.74, 43.45 , 5.02; N, 10.33. Found: C, 75.15; H, 4.99; N, 10.29 . Hz, 1H); J = 8.04 Hz, 1H); 4H); 3H); 4H); J = 8.78 Hz, 2H); 4H); 8.33 (s, 1H); 11.57 (s, 1H) . 161.01, 153.43, 149.96, 146.85, 146.58, 133.93, 139.14, 133.41, 132.89, 129.66, 129.63, 129.37, 128.82, 128.22, 128.07, 127.86, 127.56, 126.98, 126.59, 124.92, 124.26, 123.18, 114.75, 112.44, 104.02, 63.15, 56.46, 55.72, 43.52 : C, 72.85; H, 4.67; N, 9.99. Found: C, 72.74; H, 4.66; N, 9.96 . J = 8.08 Hz, 1H); J = 8.84 Hz, 2H); 7.23 (s, 2H); 3H); J = 8.84 Hz, 1H); J = 8.76 Hz, 2H); J = 7.88 Hz, 1H); 4H); 8.01 (s, 1H); 8.33 (s, 1H); 11.57 (s, 1H) . 163.07, 161.08, 149.72, 146.89, 146.43, 139.54, 134.12, 133.39, 132.90, 131.37, 129.67, 129.40, 129.25, 128.20, 128.08, 127.56, 126.98, 126.63, 125.11, 124.24, 123.51, 114.75, 112.60, 63.20, 60.32, 55.72, 43.42 , 4.87; N, 10.02; . Found: C, 72.90; H, 4.85; N, 9.98 . J = 7.68 Hz, 1H); J = 8.80 Hz, 2H); 7.23 (s, 2H); 2H); 4H); J = 9.08 Hz, 2H); 6H); 8.33 (s, 1H); 11.58 (s, 1H) . 163.08, 161.07, 148.79, 146.89, 146.47, 139.53, 134.11, 133.39, 132.90, 131.27, 129.67, 129.40, 129.25, 128.20, 128.08, 127.56, 126.98, 126.63, 125.11, 124.24, 123.51, 114.75, 112.60, 63.20, 60.42, 55.72, 43.42 , 4.87; N, 10.02. Found: C, 72.91; H, 4.86; N, 9.99 . Hz, 1H); J = 7.96 Hz, 1H); J = 8.80 Hz, 2H); 7.23 (s, 2H); 2H); 2H); 3H); 1H); 4H); 1H); 8.32 (s, 1H); 11.56 (s, 1H) . 13 C-NMR (DMSO-d 6 ): 163.07, 161.08, 149.79, 146.78, 146.47, 139.52, 134.12, 133.39, 132.87, 131.27, 129.67, 129.40, 129.25, 128.20, 128.08, 127.56, 126.98, 126.63, 125.11, 124.24, 123.51, 114.75, 112.60, 60.52, 55.72, 43.42 : C, 68.81; H, 4.42; N, 9.44; O, 5.39. Found: C, 68.69; H, 4.41; N, 9.41 . 161.08, 148.56, 146.82, 146.47, 139.71, 133.38, 132.90, 131.60, 129.67, 129.40, 128.94, 128.43, 128.25, 127.55, 126.98, 126.63, 125.11, 124.23, 123.53, 122.83, 114.75, 112.61, 63.40, 55.73, 43.12 , 4.51; N, 9.28. Found: C, 67.54; H, 4.50; N, 9.25 . 148.86, 146.89, 146.47, 139.71, 133.38, 132.90, 131.60, 129.67, 129.40, 128.94, 128.43, 128.25, 127.55, 126.98, 126.63, 125.11, 124.23, 123.53, 122.83, 114.75, 112.61, 63.40, 55.73, 43.12 Biotechnology, Nanjing University, and were determined by a standard (MTT)-based colorimetric assay (Beyotime Inst. Biotech., Nanjing, China). Tumor cell lines were grown to mid-log phase and then diluted to 5ˆ10 3 -1ˆ10 4 cells/mL making sure they were seeded in 96-well plates (Philas, Nanjing, China) at a density of 5ˆ10 3 -1ˆ10 4 cells per well. The outer wells containing 1ˆPBS solution of the plate are not used for the assay to avoid the possibility of edge effects. The plate was incubated at 37˝C in a 5% CO 2 incubator in DMEM containing 10% fetal bovine serum (FBS, Gibco, Waltham, MA, USA) for 24 h. Then, we added a 100-µL series concentration of drug-containing medium into the wells to maintain the final concentration of drug as 100, 10, 1 and 0.1 µmol/L. After 12 h, cell survival was determined by the addition of a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl trtrazolium bromide) solution (10 µL of 5 mg/mL MTT in 1ˆPBS). We waited for 4 h proliferation, discarded the medium and quickly added 150 µL DMSO per well, shaking the plates well for 10 min to ensure complete dissolution. Optical absorbance was measured at 570 nm on a microplate reader (Bio-Rad, Hercules, CA, USA). Survival ratios are expressed in percentages with respect to untreated cells. The experiments were replicated at least three times to verify the methodology reproducibility when using the above-mentioned conditions. The results were summarized in Table 2. 3.3.2. Kinase Assay EGFR tyrosine kinase activity was determined by an enzyme linked-immunosorbent assay (ELISA) in 96-well plates precoated in a 10 mL reaction volume including 4 mL diluted test compounds, 4 mL substrate and 2 mL ATP. After incubation for 1 h at 37˝C, the reactions were stopped with 10 mL 2% (v/v) H 3 PO 4 . The plates were then aspirated and washed twice with 200 mL 0.9% (w/v) NaCl, and incorporation of Pi was determined with an LX300 Epson Diagnostic microplate reader. The residual kinase activities for each concentration of compound and the compound IC 50 values were expressed in percentages with respect to untreated cells. The experiments were replicated at least three times to verify the methodology reproducibility when using the above-mentioned conditions. The results were summarized in Table 3 .
Cytotoxicity Assay
The cytotoxic activity in vitro was measured by the colorimetric MTT assay. Cells were incubated in a 96-well plate at a density of 10 5 cells per well with various concentrations of compounds (160, 40, 10, 2.5, 0.25 µM) in distilled 10% DMSO (10 µL) for 24 h. For the cytotoxicity assay, 20 µL of MTT (5 mg/mL) was added per well 4 h before the end of the incubation. After removing the supernatant, 200 µL DMSO was added to dissolve the formazan crystals. The absorbance at λ 570 nm was read on an LX300 Epson Diagnostic microplate reader, untreated cells were used as negative controls. The results are summarized in Table 4 .
Cell Apoptosis Assay by Flow Cytometry
For Annexin V/PI assays, HeLa cells were stained with Annexin VFITC and PI and then monitored for apoptosis by flow cytometry. Briefly, 5ˆ10 3 cells were seeded in 6-well plates for 24 h and then were treated with H20 (2.0, 4.0, 6.0, 8 .0 µM) for 24 h. Then, cells were collected and washed twice with PBS and stained with 5 µL Annexin V-FITC and 5 µL PI (5 µg/mL) in 1ˆbinding buffer (10 mM HEPES, pH 7.4, 140 mM NaOH, 2.5 mM CaCl 2 ) for 15 min at room temperature in the dark. Apoptotic cells were quantified using a BD Accuri C 6 Flow Cytometer (Becton, Dickinson and Company, Clifton, NJ, USA). Statistical analysis was done using Flowjo 7.6.1 software. Both early apoptotic (AnnexinV-positive, PI-negative) and late apoptotic (double positive of Annexin V and PI) cells were detected.
Docking Simulations
The crystal structures of the proteins complex were retrieved from the RCSB Protein Data Bank (PDB code: 1M17). Then, three-dimensional structures of the aforementioned compounds were constructed using Chem 3D Ultra 14.0 software (Cambridge Soft Corporation, Boston MA, USA), then they were energetically minimized by using MMFF94 with 5000 iterations and minimum RMS gradient of 0.10. Molecular docking of compound H20 into the three-dimensional EGFR complex structure was carried out using the Discovery Studio (Discovery Studio 4.5, Accelrys, Co. Ltd., Beijing, China) software as implemented through the graphical user interface DS-CDOCKER protocol. All bound waters and ligands were eliminated from the protein and the polar hydrogen was added to the proteins. Briefly, we define the EGFR complex as a receptor, then perform simulation of the compound into the ATP binding site in EGFR by replacing ATP molecule with our compound H20.
Conclusions
A series of benzohydrazide derivatives H1-H32 containing dihydropyrazoles were synthesized and evaluated in vitro for anticancer activities against the A549, MCF-7, HeLa and HepG2 cell lines, EGFR inhibitory activities, as well as MTT assays. These compounds exhibited potent EGFR inhibitory activities and antiproliferative activities against the above four cell lines. Among them, compound H20 showed the most potent EGFR inhibition activities (IC 50 = 0.08 µM) and anticancer activities against A549, HeLa and HepG2 (IC 50 = 0.46, 0.29, 0.15 and 0.21 µM, respectively) . Docking simulation of the binding model of compound H20 with EGFR indicated that conventional hydrogen bonds and Van der Waals interactions with the protein residues in the ATP binding site might play a crucial role in its EGFR inhibition and antiproliferative activities. Therefore, compound H20 may be developed as a potential antitumor agent. Author Contributions: Haichao Wang and Hailiang Zhu conceived, designed and performed the synthetic experiment part; Hongxia Li analyzed the data; Xiaoqiang Yan conceived, designed and performed the docking simulation study part; Tianlong Yan conceived, designed and performed the pharmacological test part; Haichao Wang wrote the paper. Xiaoqiang Yan, Zhongchang Wang and Hailiang Zhu assisted with the paper revision.
